210 related articles for article (PubMed ID: 30137199)
41. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus.
Zhang X; Komaki R; Wang L; Fang B; Chang JY
Clin Cancer Res; 2008 May; 14(9):2813-23. PubMed ID: 18451249
[TBL] [Abstract][Full Text] [Related]
42. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
Jiang H; Rivera-Molina Y; Gomez-Manzano C; Clise-Dwyer K; Bover L; Vence LM; Yuan Y; Lang FF; Toniatti C; Hossain MB; Fueyo J
Cancer Res; 2017 Jul; 77(14):3894-3907. PubMed ID: 28566332
[TBL] [Abstract][Full Text] [Related]
43. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus.
Tong Y; Zhu W; Huang X; You L; Han X; Yang C; Qian W
Oncol Rep; 2014 Apr; 31(4):1581-8. PubMed ID: 24535016
[TBL] [Abstract][Full Text] [Related]
44. The antitumor effects of oncolytic adenovirus H101 against lung cancer.
Lei J; Li QH; Yang JL; Liu F; Wang L; Xu WM; Zhao WX
Int J Oncol; 2015 Aug; 47(2):555-62. PubMed ID: 26081001
[TBL] [Abstract][Full Text] [Related]
45. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
46. Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC).
Yang F; Shi P; Xi X; Yi S; Li H; Sun Q; Sun M
Med Oncol; 2006; 23(2):191-204. PubMed ID: 16720919
[TBL] [Abstract][Full Text] [Related]
47. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
48. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
49. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway.
Shamimi-Noori S; Yeow WS; Ziauddin MF; Xin H; Tran TL; Xie J; Loehfelm A; Patel P; Yang J; Schrump DS; Fang BL; Nguyen DM
Cancer Gene Ther; 2008 Jun; 15(6):356-70. PubMed ID: 18309355
[TBL] [Abstract][Full Text] [Related]
50. Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft.
Wang Y; He L; He G; Kong Y; Liu X; Cai H; Liu X; Tan W
Sheng Wu Gong Cheng Xue Bao; 2010 Jun; 26(6):780-8. PubMed ID: 20815258
[TBL] [Abstract][Full Text] [Related]
51. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells.
Aydin C; Sanlioglu AD; Karacay B; Ozbilim G; Dertsiz L; Ozbudak O; Akdis CA; Sanlioglu S
Hum Gene Ther; 2007 Jan; 18(1):39-50. PubMed ID: 17187448
[TBL] [Abstract][Full Text] [Related]
52. Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo.
Zhang H; Sui A; Wang Z; Liu S; Yao R
Int J Mol Med; 2012 Aug; 30(2):358-64. PubMed ID: 22614533
[TBL] [Abstract][Full Text] [Related]
53. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.
Jin J; Liu H; Yang C; Li G; Liu X; Qian Q; Qian W
Mol Cancer Ther; 2009 May; 8(5):1387-97. PubMed ID: 19417152
[TBL] [Abstract][Full Text] [Related]
54. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
55. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest.
Kang S; Kang D; Bakhtiar Ul Islam SM; Je S; Kim JH; Song JJ
Cell Signal; 2015 Jun; 27(6):1214-24. PubMed ID: 25748050
[TBL] [Abstract][Full Text] [Related]
56. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
[TBL] [Abstract][Full Text] [Related]
57. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
58. Oncolytic Bovine Herpesvirus 1 Inhibits Human Lung Adenocarcinoma A549 Cell Proliferation and Tumor Growth by Inducing DNA Damage.
Qiu W; Ding X; Li S; He Y; Zhu L
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445287
[TBL] [Abstract][Full Text] [Related]
59. Biosilicified oncolytic adenovirus for cancer viral gene therapy.
Kong H; Zhao R; Zhang Q; Iqbal MZ; Lu J; Zhao Q; Luo D; Feng C; Zhang K; Liu X; Kong X
Biomater Sci; 2020 Oct; 8(19):5317-5328. PubMed ID: 32779647
[TBL] [Abstract][Full Text] [Related]
60. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC
Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
